当前位置: X-MOL 学术Neoplasia › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression.
Neoplasia ( IF 4.8 ) Pub Date : 2019-06-22 , DOI: 10.1016/j.neo.2019.05.007
Hui Liu 1 , Zhen Wu 1 , Haibin Zhou 1 , Wenjie Cai 1 , Xinjun Li 1 , Jing Hu 1 , Lin Gao 1 , Tingting Feng 1 , Lin Wang 1 , Xijia Peng 1 , Mei Qi 2 , Long Liu 2 , Bo Han 3
Affiliation  

Although androgen-deprivation treatment (ADT) is the main treatment for advanced prostate cancer (PCa), it eventually fails. This failure invariably leads to castration-resistant prostate cancer (CRPC) and the development of the neuroendocrine (NE) phenotype. The molecular basis for PCa progression remains unclear. Previously, we and others have demonstrated that the sex-determining region Y-box 4 (SOX4) gene, a critical developmental transcription factor, is overexpressed and associated with poor prognosis in PCa patients. In this study, we show that SOX4 expression is associated with PCa progression and the development of the NE phenotype in androgen deprivation conditions. High-throughput microRNA profiling and bioinformatics analyses suggest that SOX4 may target the miR-17-92 cluster. SOX4 transcriptionally upregulates miR-17-92 cluster expression in PCa cells. SOX4-induced PCa cell proliferation, migration, and invasion are also mediated by miR-17-92 cluster members. Furthermore, RB1 is a target gene of miR-17-92 cluster. We found that SOX4 downregulates RB1 protein expression by upregulating the miR-17-92 expression. In addition, SOX4-knockdown restrains NE phenotype and PCa cell proliferation. Clinically, the overexpression of miR-17-92 members is shown to be positively correlated with SOX4 expression in PCa patients, whereas RB1 expression is negatively correlated with SOX4 expression in patients with the aggressive PCa phenotype. Collectively, we propose a novel model of a SOX4/miR-17-92/RB1 axis that may exist to promote PCa progression.

中文翻译:

SOX4 / miR-17-92 / RB1轴促进前列腺癌的进展。

尽管雄激素剥夺治疗(ADT)是晚期前列腺癌(PCa)的主要治疗方法,但最终失败。这种失败总是导致去势抵抗性前列腺癌(CRPC)和神经内分泌(NE)表型的发展。PCa进展的分子基础仍然不清楚。以前,我们和其他人已经证明,性别决定区域Y-box 4(SOX4)基因是一种重要的发育转录因子,在PCa患者中过表达并且与不良预后相关。在这项研究中,我们表明SOX4表达与雄激素剥夺条件下PCa的进展和NE表型的发展有关。高通量microRNA分析和生物信息学分析表明,SOX4可能靶向miR-17-92簇。SOX4转录上调PCa细胞中miR-17-92簇的表达。SOX4诱导的PCa细胞增殖,迁移和侵袭也由miR-17-92簇成员介导。此外,RB1是miR-17-92簇的靶基因。我们发现SOX4通过上调miR-17-92表达来下调RB1蛋白的表达。此外,SOX4组合可抑制NE表型和PCa细胞增殖。临床上,在PCa患者中,miR-17-92成员的过度表达与SOX4表达呈正相关,而在侵略性PCa表型患者中,RB1表达与SOX4表达呈负相关。集体,我们提出了可能存在以促进PCa进展的SOX4 / miR-17-92 / RB1轴的新型模型。miR-17-92簇成员也介导和侵袭。此外,RB1是miR-17-92簇的靶基因。我们发现SOX4通过上调miR-17-92表达来下调RB1蛋白的表达。此外,SOX4组合可抑制NE表型和PCa细胞增殖。临床上,在PCa患者中,miR-17-92成员的过度表达与SOX4表达呈正相关,而在侵略性PCa表型患者中,RB1表达与SOX4表达呈负相关。集体,我们提出了可能存在以促进PCa进展的SOX4 / miR-17-92 / RB1轴的新型模型。miR-17-92簇成员也介导和侵袭。此外,RB1是miR-17-92簇的靶基因。我们发现SOX4通过上调miR-17-92表达来下调RB1蛋白的表达。此外,SOX4组合可抑制NE表型和PCa细胞增殖。临床上,在PCa患者中,miR-17-92成员的过度表达与SOX4表达呈正相关,而在侵略性PCa表型患者中,RB1表达与SOX4表达呈负相关。集体,我们提出了可能存在以促进PCa进展的SOX4 / miR-17-92 / RB1轴的新型模型。SOX4-nockdown抑制NE表型和PCa细胞增殖。临床上,在PCa患者中,miR-17-92成员的过度表达与SOX4表达呈正相关,而在侵略性PCa表型患者中,RB1表达与SOX4表达呈负相关。集体,我们提出了可能存在以促进PCa进展的SOX4 / miR-17-92 / RB1轴的新型模型。SOX4-nockdown抑制NE表型和PCa细胞增殖。临床上,在PCa患者中,miR-17-92成员的过度表达与SOX4表达呈正相关,而在侵略性PCa表型患者中,RB1表达与SOX4表达呈负相关。集体,我们提出了可能存在以促进PCa进展的SOX4 / miR-17-92 / RB1轴的新型模型。
更新日期:2019-06-22
down
wechat
bug